1. Aapro, M., 2002. 5-HT3 receptor antagonists: are they all the same? Management of nausea and vomiting: revisiting the role of the 5-HT3 receptor antagonists. Cancer Today (Suppl. 1), 3–15.
2. The mechanism of emesis induced by anti-cancer agent therapies;Andrews,1993
3. Anzemet® tablets (dolasetron mesylate) Prescribing Information, 2000. Aventis Pharmaceuticals, Kansas City, MO.
4. Aprepitant FDA advisory committee background package, March 6, 2003. http://fda.gov/ohrms/dockets/ac/03/briefing/3928b1.htm
5. ASHP, 1999. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. American Journal of Health-System Pharmacy 56, 729–764.